PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.79%
Cash & equivalents declining -35.79% while AGEN's grows 49.31%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-35.79%
Below half of AGEN's 49.31%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.27%
Above 1.5x AGEN's -9.56%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-32.53%
Below half of AGEN's 18.76%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-2.15%
Below half AGEN's 26.24%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.04%
Less than half of AGEN's 1.62%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-1.56%
Below half of AGEN's 12.33%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-28.33%
Below half of AGEN's 15.91%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-12.11%
Less than half of AGEN's 8.76%. David Dodd sees a more disciplined AP approach or lower volume.
-29.66%
Higher Short-Term Debt Growth compared to AGEN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
6.29%
Below half of AGEN's 17.30%. Michael Burry suspects a big gap in pre-sales traction.
100.00%
Exceeding 1.5x AGEN's 13.59%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-11.86%
Less than half of AGEN's 4.20%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AGEN's -4.37%. Michael Burry suspects a looming risk from large additions to LT liabilities.
-7.08%
Above 1.5x AGEN's -3.50%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-11.32%
Above 1.5x AGEN's -1.06%. Michael Burry sees a potential leverage warning sign.
6.25%
Less than half of AGEN's 18.51%. David Dodd sees fewer share issuances vs. competitor.
-2.72%
0.75-0.9x AGEN's -3.48%. Bill Ackman questions if competitor reinvests profits more robustly.
100.00%
Similar yoy to AGEN's 92.67%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
-46.50%
Below half AGEN's 13.06%. Michael Burry sees potential underperformance in building shareholder capital.
-28.33%
Below half AGEN's 15.91%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.76%
Less than half of AGEN's 25.93%. David Dodd sees less overall debt expansion vs. competitor.
40.72%
Less than half of AGEN's -63.55%. David Dodd sees better deleveraging or stronger cash buildup than competitor.